Media headlines about Amedisys (NASDAQ:AMED) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amedisys earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media stories about the health services provider an impact score of 46.9363179185042 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
AMED has been the topic of several recent analyst reports. William Blair reaffirmed an “outperform” rating on shares of Amedisys in a research report on Tuesday, November 21st. BidaskClub cut Amedisys from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $61.00 price objective on the stock in a research report on Friday, January 12th. Jefferies Group set a $70.00 price objective on Amedisys and gave the company a “buy” rating in a research report on Wednesday, February 28th. Finally, Oppenheimer increased their price objective on Amedisys from $68.00 to $63.00 and gave the company an “outperform” rating in a research report on Thursday, March 1st. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $63.18.
Amedisys (NASDAQ:AMED) opened at $61.38 on Thursday. Amedisys has a 1-year low of $45.60 and a 1-year high of $65.91. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.45 and a quick ratio of 1.45. The firm has a market capitalization of $2,093.46, a PE ratio of 69.75, a price-to-earnings-growth ratio of 1.05 and a beta of 0.62.
ILLEGAL ACTIVITY NOTICE: This news story was posted by BBNS and is the sole property of of BBNS. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://baseballnewssource.com/2018/03/15/amedisys-amed-receives-daily-coverage-optimism-rating-of-0-20/2036668.html.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.